Publication
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (13)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 13
- cancerBladder Carcinomacivic_curation1.00
- cancerCholangiocarcinomacivic_curation1.00
- cancerLung Squamous Cell Carcinomacivic_curation1.00
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugInfigratinibcivic_curation1.00
- geneFGFR1civic_curation1.00
- geneFGFR2civic_curation1.00
- geneFGFR3civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
- variantFGFR2 Fusioncivic_curation1.00
- variantFGFR2 Fusioncivic_curation1.00
- variantFGFR2 Mutationcivic_curation1.00
- variantFGFR3 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (7)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27870574
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Amplification3 | ||||||||
| Infigratinib | Bladder Carcinoma | Predictive | C | Does Not Support Sensitivity Response | 2 | accepted | EID1911Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Of the eight patients with FGFR3-mutated bladder/urothelial cancer, one patient with FGFR1 amplification was treated wi… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC | civic |
| 〃 | Lung Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1908Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). In the subgroup of FGFR1-amplified squamous NSCLC (as classified by FISH), 36 patients were trea… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Breast Neoplasm | Predictive | B | Does Not Support Resistance | 2 | accepted | EID1909Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). Among the 21 continuously treated (>100mg) patients with breast cancer and FGFR1 amplification (… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC | civic |
| FGFR3 Mutation1 | ||||||||
| Infigratinib | Bladder Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1910Phase 1 study evaluated 132 patients who had advanced cancer with FGFR-aberrations treated with FGFR-inhibitor BGJ398. In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer tr… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC | civic |
| FGFR3 R248C1 | ||||||||
| Infigratinib | Bladder Carcinoma | Predictive | B | Supports Sensitivity Response | 1 | submitted | EID8318Phase 2 BGJ398 dose escalation to determine maximum tolerated dose and RP2D dose. There was Antitumor activity PR in FGFR3-mutant bladder/urothelial carcinoma. PMID 27870574 · Nogova et al., 2017 · Open in CIViC | civic |
| FGFR2 Mutation1 | ||||||||
| Infigratinib | Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1912Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among three patients with cholangiocarcinoma and FGFR2 aberrations (2 fusions, 1 mutation), all three had stable diseas… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC | civic |
| FGFR2 Fusion + FGFR2 Fusion1 | ||||||||
| Infigratinib | Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1913Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). Two cholangiocarcinoma patients harbored FGFR2 fusions. Both were treated at BGJ398 doses >100mg… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC | civic |